What is the current Price Target for the Corvus Pharmaceuticals, Inc. stock?

The average Corvus Pharmaceuticals, Inc. target price is $15.40. This is 325.41% higher than the current stock price. The highest price target is 562.98%, the lowest is 203.87%. 5 Analysts have issued a price target Corvus Pharmaceuticals, Inc. 2026 .

How high will the Corvus Pharmaceuticals, Inc. stock rise?

No reliable answer can be given as to how high the Corvus Pharmaceuticals, Inc. stock will rise. The performance of stocks, including the Corvus Pharmaceuticals, Inc. stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Corvus Pharmaceuticals, Inc. stock today?

The performance of Corvus Pharmaceuticals, Inc. stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Corvus Pharmaceuticals, Inc. stock fall?

The decline in Corvus Pharmaceuticals, Inc. stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Corvus Pharmaceuticals, Inc. Forecast, price target & analysts

$3.62

6.94% yesterday

Nasdaq, May 14, 10:00 pm CET

ISIN

US2210151005

Symbol

CRVS

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Corvus Pharmaceuticals, Inc. Target price 2025 - Analyst rating & recommendation

Corvus Pharmaceuticals, Inc. Classifications & Recommendation:

Buy

100%

Corvus Pharmaceuticals, Inc. Price Target

Target Price	$15.40
Price	$3.62
Potential	325.41% register free of charge
Number of Estimates	5

	5 Analysts have issued a price target Corvus Pharmaceuticals, Inc. 2026 . The average Corvus Pharmaceuticals, Inc. target price is $15.40. This is 325.41% register free of charge higher than the current stock price. The highest price target is $24.00 562.98% register free of charge , the lowest is $11.00 203.87% register free of charge .
	A rating was issued by 6 analysts: 6 Analysts recommend Corvus Pharmaceuticals, Inc. to buy, 0 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Corvus Pharmaceuticals, Inc. stock has an average upside potential 2026 of 325.41% register free of charge . Most analysts recommend the Corvus Pharmaceuticals, Inc. stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually

	Dec '24	2025 Estimates
Earnings Per Share $	-1.02	-0.54
	82.14%	47.06%
P/E		negative
EV/Sales		304.63

2 Analysts have issued a Corvus Pharmaceuticals, Inc. forecast for earnings per share. The average Corvus Pharmaceuticals, Inc. EPS is

Unlock

. This is

Unlock

than earnings per share in the financial year 2024. The highest EPS forecast is

Unlock

, the lowest is

Unlock

This results in the following potential growth metrics and future valuations:

2024	$-1.02	82.14%
2025	$-0.54 47.06% Unlock
2026	$-0.71 31.48% Unlock
2027	$-0.76 7.04% Unlock

Current	-3.68	9.58%
2025	-6.70 82.07% Unlock
2026	-5.13 23.43% Unlock
2027	-4.76 7.21% Unlock

Corvus Pharmaceuticals, Inc....

Current Corvus Pharmaceuticals, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more

Analyst	Rating	Action	Date
Oppenheimer	Locked ➜ Locked	Locked	May 09 2025
HC Wainwright & Co.	Locked ➜ Locked	Locked	Mar 26 2025
Oppenheimer	Locked ➜ Locked	Locked	Mar 26 2025
HC Wainwright & Co.	Locked ➜ Locked	Locked	Jan 14 2025
HC Wainwright & Co.	Locked ➜ Locked	Locked	Jan 02 2025
Oppenheimer	Locked ➜ Locked	Locked	Nov 13 2024
Ladenburg Thalmann	Locked ➜ Locked	Locked	Sep 16 2024

Analyst Rating	Date
Locked Oppenheimer: Locked ➜ Locked	May 09 2025
Locked HC Wainwright & Co.: Locked ➜ Locked	Mar 26 2025
Locked Oppenheimer: Locked ➜ Locked	Mar 26 2025
Locked HC Wainwright & Co.: Locked ➜ Locked	Jan 14 2025
Locked HC Wainwright & Co.: Locked ➜ Locked	Jan 02 2025
Locked Oppenheimer: Locked ➜ Locked	Nov 13 2024
Locked Ladenburg Thalmann: Locked ➜ Locked	Sep 16 2024

Discover more stocks with a high price target

TUI 56.43%

Novo Nordisk 55.28%

BioNTech SE - ADR 46.03%

MongoDB 35.46%

NIO ADR 28.88%

Pfizer 28.35%

Alibaba Group Holding Ltd 22.25%

Tencent Holdings Ltd. 21.31%

Deutsche Telekom 21.14%

Alphabet 19.92%

NVIDIA 18.64%

Adidas 15.81%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now